Search clinical trials for: RDX013

Total 58 results

Ardelyx

Completed

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia (Redukx)

Hyperkalemia

United States
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Affiliated Hospital of Yunnan University
Kunming Medical University; Yunnan University

Completed

A Study to Investigate the Safety, Immunogenicity of Bivalent mRNA Vaccine RQ3027 and RQ3025 as a Booster Dose in Healthy Adults

COVID-19

China
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

Severe Hemophilia A | Moderate Hemophilia A

Brazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)

Hemophilia A

United States, France, Germany, Italy, South Africa, Spain, Turkey, Japan, United Kingdom, Costa Rica
Hoffmann-La Roche

Active, not recruiting

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (HAVEN 5)

Hemophilia A

China, Thailand, Hong Kong, Malaysia
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6)

Hemophilia A | Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

United States, Netherlands, Belgium, France, Germany, South Africa, Spain, Canada, United Kingdom, Poland
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

Severe Hemophilia A

Canada, United States, United Kingdom, Belgium, Australia, Austria, Brazil, France, Germany, Israel, Italy, South Africa, Spain, Turkey
Genentech, Inc.

Terminated

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Hemophilia A

United States
GammaDelta Therapeutics Limited

Terminated

Study of GDX012 in Patients With MRD Positive AML

Acute Myeloid Leukemia

United States
Takeda

Recruiting

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States
Weijia Fang, MD
Nanjing Blue Shield Biotech Co.,Ltd

Completed

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Ovarian Cancer

China
Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers

Healthy

China
Henan Cancer Hospital
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Hematologic Malignancies

China
MEI HENG
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

Neoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic Neoplasms

China
Min Xiang

Unknown

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

T-lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia

China
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

Hypertension | Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

Hypertension and Dyslipidemia

Korea, Republic of
Xiaoyu Zhu
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

Neoplasms | Hematologic Diseases | Hematologic Neoplasms

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Neoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic Neoplasms

China
Kai Lin Xu，MD
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

Neoplasms | Hematologic Diseases | Hematologic Neoplasms

China
He Huang

Completed

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Hematologic Malignancies

China
Chong Kun Dang Pharmaceutical

Completed

A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

Hypertension | Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
M.D. Anderson Cancer Center
Mologen AG

Active, not recruiting

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Melanoma | Advanced Cancers

United States
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Dyslipidemia Patients With Hypertension

Korea, Republic of
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Stand Up To Cancer; High Impact Clinical Research Support...

Completed

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States
Bristol-Myers Squibb
Medarex

Completed

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Advanced Melanoma

United States
Bristol-Myers Squibb

Completed

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Prostate Cancer

United States, France, Mexico, Sweden, Canada, Australia, Italy, Colombia, Denmark, Argentina, Chile, Spain, Germany, Puerto Rico, United Kingdom, Czech Republic, Romania, Norway, Poland, Netherlands, Brazil, Hungary, Turkey, Greece
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

Hypertension and Dyslipidemia

Korea, Republic of
Kristen Ganjoo
Bristol-Myers Squibb

Completed

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Ipilimumab + Temozolomide in Metastatic Melanoma

Metastatic Melanoma

United States
Robert R. McWilliams, MD
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

Unknown

A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Patient of Anemia in Chronic Renal Failure With Hemodialysis

China
M.D. Anderson Cancer Center

Recruiting

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

Lung Cancer | Liver Cancer

United States
Melanoma and Skin Cancer Trials Limited
Bristol-Myers Squibb; Amgen; Peter MacCallum Cancer Centre, Australia

Active, not recruiting

Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (CHARLI)

Melanoma | Melanoma Stage Iv | Melanoma Stage Iii

Australia
Andrew J. Armstrong, MD
Bristol-Myers Squibb

Recruiting

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)

Metastatic Prostate Cancer | Metastatic Prostate Neuroendocrine Carcinoma

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

Hypertension | Dyslipidemias

Korea, Republic of
M.D. Anderson Cancer Center

Completed

Ipilimumab and Lenalidomide in Advanced Cancer

Advanced Cancers

United States
NYU Langone Health

Recruiting

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma | Unresectable Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Doxycycline, Temozolomide and Ipilimumab in Melanoma

Melanoma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Neoadjuvant Ipilimumab in Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Celgene

Completed

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Melanoma | Sarcoma
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Prostate Cancer

United States

Search clinical trials for: RDX013

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations